Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 9102 results

  1. Surgical mesh for treatment of primary ventral hernias

    In development Reference number: GID-HTG10876 Expected publication date:  24 June 2027

    HealthTech guidance
    In development

  2. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTG10888 Expected publication date:  06 January 2027

    HealthTech guidance
    In development

  3. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTG10883 Expected publication date:  11 February 2027

    HealthTech guidance
    In development

  4. Inavolisib with pertuzumab–trastuzumab for maintenance treatment of PIK3CA-mutated HER2-positive advanced breast cancer after induction chemotherapy

    Awaiting development Reference number: GID-TA12441 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date:  04 June 2026

    Technology appraisal guidance
    In development

  6. Imlunestrant for adjuvant treatment of ER-positive, HER2-negative early breast cancer with increased risk of recurrence

    Awaiting development Reference number: GID-TA12459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTG10885 Expected publication date:  02 December 2026

    HealthTech guidance
    In development

  8. Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]

    Awaiting development Reference number: GID-TA11988 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development

  10. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]

    Awaiting development Reference number: GID-TA11954 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    In development Reference number: GID-TA11625 Expected publication date:  16 December 2026

    Technology appraisal guidance
    In development

  13. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development